General Announcement::Glenmark Pharmaceuticals receives ANDA approval for Ezetimibe and Simvastatin Tablets

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PH US$200M4.5%210802 - XS1456577334 - 4N4B
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
28-Jun-2019 11:44:55
Status
New
Announcement Sub Title
Glenmark Pharmaceuticals receives ANDA approval for Ezetimibe and Simvastatin Tablets
Announcement Reference
SG190628OTHR2Z1F
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
28/06/2019 00:00:00
Description (Please provide a detailed description of the event in the box below)
Glenmark Pharmaceuticals receives ANDA approval for Ezetimibe and Simvastatin Tablets, 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg, and 10 mg/80 mg

Attachments

PR_SGX_28062019.pdf
Total size =217K